ABL
Guillaume SIRGUE is a skilled professional with a background in BioPharmaceuticals and Fine Chemistry Processes. Guillaume currently works as a Customer Solutions Leader at ABL Europe, where Guillaume designs technical proposals in viral vector development and manufacturing. Prior to this, Guillaume held various roles at companies such as Sanofi Pasteur and Altran, gaining extensive experience in manufacturing, process development, and project leadership. Guillaume has a strong educational background, holding an Engineer's degree in Organic Chemistry and Biochemistry from Ecole Nationale Supérieure de Chimie de Montpellier.
This person is not in any teams
ABL
From development to market ABL Europe provides GMP viral vectors, contributing to the success of our clients’ immunotherapy innovations. ABL Europe SAS is a pure-play GMP CMO licensed in accordance with EMA, completely dedicated to the provision of viral vector GMP contract manufacturing services, and a subsidiary of ABL Inc. under the corporate ownership of Institut Mérieux. ABL has a strong technical & regulatory track record in process development, scale-up & GMP manufacturing of filterable & non-sterile filterable (aseptic processing) viral vectors used in all phases of clinical development globally. With different adherent platforms (< 60 m2) and suspension (< 500 L) capabilities for drug substance and drug product (< 10,000 vials per batch) in-house, experience in process characterisation and validation, ABL provides its clients with a long-term strategic manufacturing option through clinical development & licensure for a range of virus vector gene therapy & vaccine products. ABL Europe’s clients are located worldwide.